Cardiac Catheterization and Endomyocardial Biopsy

  • Robert E. Fowles

Abstract

This chapter will describe the technique and application of cardiac catheterization and biopsy in evaluating the status of patients receiving anthracyclines (doxorubicin [Adriamycin]). The pathophysiology and histopathology of anthracycline cardiotoxicity are described elsewhere in this text. We shall be concerned mainly with how to screen for, diagnose, and quantify doxorubicin cardiotoxicity, using three tools—noninvasive tests, cardiac catheterization, and endomyocardial biopsy.

Keywords

Toxicity Catheter Radionuclide Assure Doxorubicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32: 302, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Minow RA, Benjamin RS, Lee ET, Gottlieb JA: QRS voltage change with Adriamycin administration. Cancer Treat Rep 62: 931, 1978.PubMedGoogle Scholar
  3. 3.
    Jones SE, Ewy GA, Groves BM: Echocardiographic detection of Adriamycin cardiotoxicity. Proceedings American Association for Cancer Research/ASCO 16: 228, 1975.Google Scholar
  4. 4.
    Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Choi W, Berger H, Alexander J, et al: Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am J Cardiol 47: 474, 1981.CrossRefGoogle Scholar
  6. 6.
    Mason JW, Bristow MR, Billingham ME, Daniels JR: Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treatment Rep 62: 857, 1978.Google Scholar
  7. 7.
    Ewy GA, Jones SE, Friedman MJ, et al: Noninvasive cardiac evaluation of patients receiving Adriamycin. Cancer Treat Rep 62: 915, 1978.PubMedGoogle Scholar
  8. 8.
    Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50: 32, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Bristow MR, Lopez M, McKillop J, Billingham ME: Specificity and sensitivity of radionuclide ejection fractions in doxorubicin cardiomyopathy. AFCR (Am Fed Clin Res) Abstr 154, 1980.Google Scholar
  10. 10.
    Bristow MR: Pathophysiologic basis for cardiac monitoring in patients receiving anthracyclines. In Crooke ST, Reich SD (eds): Anthracyclines: Current Status and New Developments. New York, Academic Press, 1980, pp 255–271.Google Scholar
  11. 11.
    Olson HM, et al: Electrolyte and morphologic alterations of myocardium in Adriamycin-treated rabbits. Am J Pathol 77: 439, 1974.PubMedGoogle Scholar
  12. 12.
    Jaenke RS: Delayed and progressive myocardial lesions after Adriamycin administration in the rabbit. Cancer Res 36: 2958, 1976.PubMedGoogle Scholar
  13. 13.
    Fowles RE, Mason JW: Endomyocardial biopsy. Ann Intern Med 97: 885, 1982.PubMedGoogle Scholar
  14. 14.
    Billingham ME, Mason JW, Bristow MR, Daniels JR: Anathracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865, 1978.PubMedGoogle Scholar
  15. 15.
    Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102: 709, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Billingham ME, Bristow MR, Glatstein E, et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1: 17, 1977.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1986

Authors and Affiliations

  • Robert E. Fowles

There are no affiliations available

Personalised recommendations